“While the Federal Trade Commission (FTC) does not regulate the safety or manufacturing of the impacted products, it can take steps to address any anticompetitive, unfair, or deceptive acts or practices that have contributed to or are worsening this problem,” a statement from the agency said. “The FTC can also examine the infant formula industry to identify the factors that created such a fragile market, where a single disruption at a single plant can jeopardize supply.”
The shortage stems from the February shutdown of an Abbott Nutrition factory due to safety concerns. The manufacturer will release about 300,000 cans of a specialty formula for children in urgent medical need, while health regulators cleared the import of around 2 million cans from the U.K., The Wall Street Journal reported May 24.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
